Grace Lu-Yao1, Ginah Nightingale2, Nikita Nikita3, Scott Keith4, Krupa Gandhi4, Kristine Swartz5, Ralph Zinner6, Swapnil Sharma3, W M Kevin Kelly3, Andrew Chapman5. 1. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA; College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, PA, USA. Electronic address: grace.luyao@jefferson.edu. 2. Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA. 3. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, PA, USA. 4. Division of Biostatistics, Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA. 5. Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, PA, USA; Department of Medical Oncology, Jefferson Senior Adult Oncology Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA. 6. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, PA, USA; University of Kentucky Markey Cancer Center, Lexington Kentucky, USA.
Abstract
OBJECTIVES: Polypharmacy (≥5 concurrent medications) is common among older patients with cancer (48%-80%) and associated with increased frailty, morbidity, and mortality. This study examined the relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous (IV) chemotherapy. MATERIALS AND METHODS: The main data source was the Surveillance, Epidemiology, and End Results-Medicare linked files. Patients (≥65 years) were included if they were diagnosed with prostate (n = 1430), breast (n = 5490), or lung cancer (n = 7309) in 1991-2013 and received IV chemotherapy in 2011-2014. The number of medications during the six-month window pre-IV chemotherapy initiation determined polypharmacy status. Negative binomial models were used to assess the association between polypharmacy and post-chemotherapy inpatient hospitalization. The results were presented as incidence rate ratios. RESULTS: We identified 13,959 patients with prostate, breast, or lung cancer treated with IV chemotherapy. The median number of prescription medications during the six-month window pre-IV chemotherapy initiation was high: ten among patients with prostate cancer, nine among patients with breast cancer, and eleven among patients with lung cancer. Compared to patients taking <5 prescriptions, post-chemotherapy hospitalization rate for patients with prostate cancer was 42%, 75%, and 114% higher among those taking 5-9, 10-14, and 15+ medications, respectively. Patients with breast and lung cancer demonstrated similar patterns. CONCLUSION: This large population-based study found that polypharmacy during the six-month window pre-IV chemotherapy is highly predictive of post-chemotherapy inpatient hospitalization. Further studies are needed to evaluate whether medication management interventions can reduce post-chemotherapy inpatient hospitalization among older patients with cancer.
OBJECTIVES: Polypharmacy (≥5 concurrent medications) is common among older patients with cancer (48%-80%) and associated with increased frailty, morbidity, and mortality. This study examined the relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous (IV) chemotherapy. MATERIALS AND METHODS: The main data source was the Surveillance, Epidemiology, and End Results-Medicare linked files. Patients (≥65 years) were included if they were diagnosed with prostate (n = 1430), breast (n = 5490), or lung cancer (n = 7309) in 1991-2013 and received IV chemotherapy in 2011-2014. The number of medications during the six-month window pre-IV chemotherapy initiation determined polypharmacy status. Negative binomial models were used to assess the association between polypharmacy and post-chemotherapy inpatient hospitalization. The results were presented as incidence rate ratios. RESULTS: We identified 13,959 patients with prostate, breast, or lung cancer treated with IV chemotherapy. The median number of prescription medications during the six-month window pre-IV chemotherapy initiation was high: ten among patients with prostate cancer, nine among patients with breast cancer, and eleven among patients with lung cancer. Compared to patients taking <5 prescriptions, post-chemotherapy hospitalization rate for patients with prostate cancer was 42%, 75%, and 114% higher among those taking 5-9, 10-14, and 15+ medications, respectively. Patients with breast and lung cancer demonstrated similar patterns. CONCLUSION: This large population-based study found that polypharmacy during the six-month window pre-IV chemotherapy is highly predictive of post-chemotherapy inpatient hospitalization. Further studies are needed to evaluate whether medication management interventions can reduce post-chemotherapy inpatient hospitalization among older patients with cancer.
Authors: Maarit S Dimitrow; Marja S A Airaksinen; Sirkka-Liisa Kivelä; Alan Lyles; Saija N S Leikola Journal: J Am Geriatr Soc Date: 2011-07-28 Impact factor: 5.562
Authors: M-E Rougé Bugat; M Bourgouin; S Gérard; S Lozano; D Brechemier; P Cestac; C Cool; L Balardy Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Darryl Outlaw; Chen Dai; Mustafa Al-Obaidi; Christian Harmon; Smith Giri; Smita Bhatia; Grant R Williams Journal: J Geriatr Oncol Date: 2022-01-05 Impact factor: 3.929
Authors: Heidi D Klepin; Can-Lan Sun; David D Smith; Rawad Elias; Kelly M Trevino; Ashley Leak Bryant; Daneng Li; Christian Nelson; William P Tew; Supriya G Mohile; Ajeet Gajra; Cynthia Owusu; Cary Gross; Stuart M Lichtman; Vani V Katheria; Hyman B Muss; Andrew E Chapman; Harvey Jay Cohen; Arti Hurria; William Dale Journal: JCO Oncol Pract Date: 2021-04-21
Authors: Phyu Sin Aye; Oliver W Scott; J Mark Elwood; Diana Sarfati; Ross Lawrenson; Ian D Campbell; Marion Kuper-Hommel; Sandar Tin Tin Journal: Int J Environ Res Public Health Date: 2020-10-29 Impact factor: 3.390
Authors: Emelie C Rotbain; Klaus Rostgaard; Michael A Andersen; Caspar Da Cunha-Bang; Carsten U Niemann; Henrik Frederiksen; Henrik Hjalgrim Journal: Clin Epidemiol Date: 2021-12-30 Impact factor: 4.790